Th1-Biased Immunomodulation and Therapeutic Potential of Artemisia annua in Murine Visceral Leishmaniasis

PLoS Neglected Tropical Diseases

Volumn 9, Issue 1, 2015, Pages

  Islamuddin, Mohammad ^a   Chouhan, Garima ^a   Farooque, Abdullah ^b   Dwarakanath, Bilikere S ^b   Sahal, Dinkar ^c   Afrin, Farhat ^a  

^a HAMDARD UNIVERSITY   (India)

^b INSTITUTE OF NUCLEAR MEDICINE AND ALLIED SCIENCES   (India)

^c INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ARTEMISIA ANNUA EXTRACT; ARTEMISIA ANNUA LEAF EXTRACT; ARTEMISIA ANNUA SEED EXTRACT; ARTEMISININ; B7 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 10; INTERLEUKIN 4; NITRITE; UNCLASSIFIED DRUG; ANTIPROTOZOAL AGENT; CYTOKINE; IMMUNOGLOBULIN G;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTEMISIA ANNUA; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL VIABILITY; CELLULAR IMMUNITY; CHEMICAL ANALYSIS; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FREEZE THAWING; IMMUNE RESPONSE; IMMUNOLOGICAL MEMORY; IMMUNOMODULATION; LEISHMANIA DONOVANI; LIMULUS LYSATE TEST; LIVER TOXICITY; LYMPHOCYTE PROLIFERATION; MOUSE; NEPHROTOXICITY; NONHUMAN; PARASITE LOAD; PROTEIN CONTENT; PROTEIN EXPRESSION; SPLEEN WEIGHT; TH1 TH2 BALANCE; TREATMENT RESPONSE; VISCERAL LEISHMANIASIS; ANIMAL; BAGG ALBINO MOUSE; DRUG EFFECTS; IMMUNOLOGY; KIDNEY; LEISHMANIASIS, VISCERAL; LIVER; MACROPHAGE; PARASITOLOGY; PLANT LEAF; PLANT SEED; SPLEEN;

ANIMALS; ANTIPROTOZOAL AGENTS; ARTEMISIA ANNUA; CYTOKINES; FEMALE; IMMUNITY, CELLULAR; IMMUNOGLOBULIN G; IMMUNOMODULATION; INTERLEUKIN-4; KIDNEY; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; LIVER; MACROPHAGES; MICE; MICE, INBRED BALB C; PLANT LEAVES; SEEDS; SPLEEN;

EID: 84922244139     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0003321     Document Type: Article

References (67)

1. Kondrashin AV, Baranova AM, Morozova L F, Stepanova EV, (2011) Global trends in malaria control. Progress and topical tasks in malaria control programs. Med Parazitol 4: 3–8.
2. Ferrari BC, Cheung-Kwok-Sang C, Beggs PJ, Stephens N, Power ML, et al. (2011) Molecular epidemiology and spatial distribution of a waterborne cryptosporidiosis outbreak in Australia. Appl Environ Microbiol 77: 7766–7771.
3. World Health Organization (2010) Control of the leishmaniasis, World Health Organization Technical Report Series 949.186.
4. Mitropoulos P, Konidas P, Durkin-Konidas M, (2010) New World cutaneous leishmaniasis: updated review of current and future diagnosis and treatment. Journal of the American Academy of Dermatology 63: 309–322.
5. Nwaka S, Ridley RG, (2003) Virtual drug discovery and development for neglected diseases through public private partnerships. Nat Rev Drug Discov 2: 919–928.
6. Shafiei R, Mohebali M, Akhoundi B, Galian MS, Kalantar F, et al. (2013) Emergence of co-infection of visceral leishmaniasis in HIV-positive patients in northeast Iran: A preliminary study. Travel Med Infect Dis S1477-8939(13)00139-7. doi: 10.1016/j.tmaid.2013.09.001.
7. Carvalho PB, Arribas MAG, Ferreira EI, (2000) Leishmaniasis. What do we know about its chemotherapy? Rev Bras Ci Farm 36: 69–96.
8. Croft SL, Sundar S, Fairlamb AH, (2006) Drug resistance in leishmaniasis. Clin Microbiol Rev 19: 111–126.
9. Garcı'a-Herna'ndez R, Manzano JI, Castanys S, Gamarro F, (2012) Leishmania donovani Develops Resistance to Drug Combinations. PLoS Negl Trop Dis 6(12): e1974 doi:10.1371/journal.pntd.0001974
10. Cragg GM, Newmann DJ, Snader KM, (1997) Natural products in drug discovery and development. J Nat Prod 60: 52–60.
11. Van Wyk BE, Wink M (2010) Medicinal Plants of the World: An Illustrated Scientific Guide to World Health Organization (WHO). Working to Overcome the Global Impact of Neglected Tropical Diseases: First WHO Report on Neglected Tropical Diseases; WHO: Geneva, Switzerland, 2010; No.1.
12. Tiuman TS, Santos AO, Ueda-Nakamura T, Filho BPD, Nakamura CV, (2011) Recent advances in leishmaniasis treatment. Int J Infect Dis 15: 525–532.
13. Gurunathan S, Stobie L, Prussin C, Sacks DL, Glaichenhaus N, et al. (2000) Requirements for the maintenance of Th1 immunity in vivo following DNA vaccination: a potential immunoregulatory role for CD8+ T cells. J Immunol 165: 915–924.
14. Banerjee A, De M, Ali N, (2011) Combination Therapy with Paromomycin-Associated Stearylamine-Bearing Liposomes Cures Experimental Visceral Leishmaniasis through Th1-Biased Immunomodulation. Antimicrob Agents Chemother 55: 1661–1670.
15. Gautam M, Saha S, Bani S, Kaul A, Mishra S, et al. (2009) Immunomodulatory activity of Asparagus racemosus on systemic Th1/Th2 immunity: implications for immunoadjuvant potential. J Ethnopharmacol 121: 241–247.
16. Zaph C, Uzonna J, Beverley SM, Scott P, (2004) Central memory T cells mediate long-term immunity to Leishmania major in the absence of persistent parasites. Nature medicine 10: 1104–1110.
17. Berger BJ, Fairlamb AH, (1992) Interactions between immunity and chemotherapy in the treatment of trypanosomiases and leishmaniases. Parasitology 105: 71–78.
18. Rocha LG, Almeida JR, Macedo RO, Barbosa-Filho JM, (2005) A review of natural products with antileishmanial activity. Phytomedicine 12: 514–535.
19. Tan BK, Vanitha J, (2004) Immunomodulatory and antimicrobial effects of some traditional chinese medicinal herbs: a review. Curr Med Chem. 11: 1423–30.
20. Weathers PJ, Jordan NJ, Lasin P, Towler MJ, (2014) Simulated digestion of dried leaves of Artemisia annua consumed as a treatment (pACT) for malaria. J Ethnopharmacol 151: 858–863.
21. Suberu JO, Gorka AP, Jacobs L, Roepe PD, Sullivan N, et al. (2013) Anti-plasmodial polyvalent interactions in Artemisia annua L. aqueous extract–possible synergistic and resistance mechanisms. PLoS One 8: e80790 doi:10.1371/journal.pone.0080790
22. Tran KQ, Tin AS, Firestone GL, (2014) Artemisinin triggers a G1 cell cycle arrest of human Ishikawa endometrial cancer cells and inhibits cyclin-dependent kinase-4 promoter activity and expression by disrupting nuclear factor-κB transcriptional signaling. Anticancer Drugs 25: 270–281.
23. Hou J, Wang D, Zhang R, Wang H, (2008) Experimental Therapy of Hepatoma with Artemisinin and Its Derivatives: In vitro and In vivo Activity, Chemosensitization, and Mechanisms of Action. Clin Cancer Res 14: 5519–5530.
24. Sen R, Ganguly S, Saha P, Chatterjee M, (2010) Efficacy of artemisinin in experimental visceral leishmaniasis. Int J Antimicrob Ag 36: 43–49.
25. Ferreira JFS, Luthria DL, Sasaki T, Heyerick A, (2010) Flavonoids from Artemisia annua L. as Antioxidants and Their Potential Synergism with Artemisinin against Malaria and Cancer. Molecules 15: 3135–3170.
26. Islamuddin M, Farooque A, Dwarakanath BS, Sahal D, Afrin F, (2012) Extract of Artemisia annua leaves and seeds mediate programmed cell death in Leishmania donovani J Med Microbiol. 61: 1709–1718.
27. Varela-M RE, Villa-Pulgarin JA, Yepes E, Müller I, Modolell M, et al. (2012) In Vitro and In Vivo Efficacy of Ether Lipid Edelfosine against Leishmania spp. And SbV-Resistant Parasites. PLoS Negl Trop Dis 6: e1612 doi:10.1371/journal.pntd.0001612
28. Dutta A, Sarkar D, Gurib-Fakim A, Mandal C, Chatterjee M, (2008) In vitro and in vivo activity of Aloe vera leaf exudates in experimental visceral leishmaniasis. Parasitol Res 102: 1235–1242.
29. Maasho K, Akuffo HO (1992) Cells from healthy non-exposed individuals produce cytokines to selected fractions of Leishmania promastigotes. Scand J Immunol Suppl 11: 179–184.
30. Abdian N, Gholami E, Zahedifard F, Safaee N, Rafati S, (2011) Evaluation of DNA/DNA and prime-boost vaccination using LPG3 against Leishmania major infection in susceptible BALB/c mice and its antigenic properties in human leishmaniasis. Exp Parasitol 127: 627–636.
31. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ, (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265–275.
32. Seo YC, Choi WY, Lee CG, Cha SW, Kim YO, et al. (2011) Enhanced immunomodulatory activity of Gelatin-Encapsulated Rubus coreanus Miquel Nanoparticles. Int J Mol Sci 12: 9031–9056.
33. Del-Rey MJ, Manzanares J, Bosque A, Aguilo JI, Gómez-Rial J, et al. (2007) Auto-immune lymphoproliferative syndrome (ALPS) in a patient with a new germline Fas gene mutation. Immunobiology 212: 73–83.
34. Wang YP, Li XY, (2002) Effect of astragaloside IV on T, B lymphocyte proliferation and peritoneal macrophage function in mice. Acta Pharmacol Sin 3: 263–266.
35. Ding AH, Nathan CF, Stuehr DJ (1988) Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages: comparison of activating cytokines and evidence for independent production. J Immunol 141: 2407–2412
36. Agarwal V, Sharma AK, Upadhyay A, Singh G, Gupta R, (2012) Hypoglycemic effects of Citrullus colocynthis roots. Acta Pol Pharm 69: 75–79.
37. Gupta A, Khajuria A, Singh J, Bedi KL, Satti NK, et al. (2006) Immunomodulatory activity of biopolymeric fraction RLJ-NE-205 from Picrorhiza kurroa. Int Immuno-pharmacol 6: 1543–1549.
38. Khan S, Malik F, Suri KA, Singh J, (2009) Molecular insight into the immune up-regulatory properties of the leaf extract of Ashwagandha and identification of Th1 immuno stimulatory chemical entity. Vaccine 27: 6080–6087.
39. Alexander N, Moyeed R, Stander J, (2000) Spatial modelling of individual-level parasite counts using the negative binomial distribution. Biostatistics 1: 453–463.
40. Carvalho EM, Bacellar O, Brownell C, Regis T, Coffman RL, et al. (1994) Restoration of IFN-γ production and lymphocyte proliferation in visceral leishmaniasis. J Immunol 152: 5949–5956.
41. Gifawesen C, Farrell JP, (1989) Comparison of T-cell responses in self-limiting versus progressive visceral Leishmania donovani infections in golden hamsters. Infect Immun 57: 3091–3096.
42. Haldar JP, Ghose S, Saha KC, Ghose AC, (1983) Cell-mediated immune response in Indian kala-azar and post-kala-azar dermal leishmaniasis. Infect Immun 42: 702–707.
43. Lang T, Ave P, Huerre M, Milon G, Antoine JC, (2000) Macrophage subsets harbouring Leishmania donovani in spleens of infected BALB/c mice: localization and characterization. Cell Microbiol 2: 415–430.
44. Belkaid Y, Von Stebut E, Mendez S, Lira R, Caler E, et al. (2002) CD8+ T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major. J Immunol 168: 3992–4000.
45. Singh N, Kumar A, Gupta P, Chand K, Samant M, et al. (2008a) Evaluation of antileishmanial potential of Tinospora sinensis against experimental visceral leishmaniasis. Parasitol Res 102: 561–565.
46. Singh N, Kumar R, Gupta S, Dube A, Lakshmi V, (2008b) Antileishmanial activity in vitro and in vivo of constituents of sea cucumber Actinopyga lecanora. Parasitol Res 103: 351–354.
47. Monzote L, Montalvo AM, Almanonni S, Scull R, Miranda M, et al. (2006) Activity of the Essential Oil from Chenopodium ambrosioides Grown in Cuba against Leishmania amazonensis. Chemotherapy 52: 130–136.
48. Monzote L, García M, Scull R, Cuellar A, Setzer WN (2013) Antileishmanial Activity of the Essential Oil from Bixa orellana. Phytother Res doi: 10.1002/ptr.5055.
49. Basak SK, Saha B, Bhattacharya A, Roy S, (1992) Immunobiological studies on experimental visceral leishmaniasis. II. Adherent cell-mediated down-regulation of delayed-type hypersensitivity response and up-regulation of B cell activation. Eur J Immunol 22: 2041–2045.
50. Kuby J (2007) Immunology. 5th ed. New York, USA:WH freeman and Company
51. Grimaldi Jr G, Tesh RB, (1993) Leishmaniases of the new world: current concepts and implications for future research. Clin Microbiol Rev 6: 230–250.
52. Sachdeva H, Sehgal R, Kaur S, (2014) Asparagus racemosus ameliorates cisplatin induced toxicities and augments its antileishmanial activity by immunomodulation in vivo. Parasitol Int 63: 21–30.
53. Coffman RL, Lebman DA, Rothman P, (1993) Mechanism and regulation of immunoglobulin isotype switching. Adv Immunol 54: 229–270.
54. Gautam M, Diwanay S, Gairola S, Shinde Y, Patki P, et al. (2004) Immunoadjuvant potential of Asparagus racemosus aqueous extract in experimental system. J Ethnopharmacol 91: 251–255.
55. Bhattacharjee S, Gupta G, Bhattacharya P, Adhikari A, Majumdar SB, et al. (2009) Anti IL-10 mAb protection against experimental visceral leishmaniasis via induction of Th1 cytokines and nitric oxide. Indian J Exp Biol 47: 489–97.
56. Gomes R, Teixeira C, Teixeira MJ, Oliveira F, Menezes MJ, et al. (2008) Immunity to a salivary protein of a sand fly vector protects against the fatal outcome of visceral leishmaniasis in a hamster model. Proc Natl Acad Sci 105: 7845–7850.
57. Bogdan C, (2008) Mechanisms and consequences of persistence of intracellular pathogens: leishmaniasis as an example. Cell Microbiol 10: 1221–1234.
58. Polley R, Stager S, Prickett S, Maroof A, Zubairi S, et al. (2006) Adoptive immunotherapy against experimental visceral leishmaniasis with CD8+ T cells requires the presence of cognate antigen. Infect Immun 74: 773–776.
59. Murray HW, (2005) Prevention of relapse after chemotherapy in a chronic intracellular infection: mechanisms in experimental visceral leishmaniasis. J Immunol 174: 4916–4923.
60. Abid S, Khajuria A, Parvaiz Q, Sidiq T, Bhatia A, et al. (2012) Immunomodulatory studies of a bioactive fraction from the fruit of Prunus cerasus in BALB/c mice. Int Immunopharmacol 12: 626–634.
61. Curtsinger JM, Mescher MF, (2010) Inflammatory cytokines as a third signal for T cell activation. Curr Opin Immunol 22: 333–340.
62. Gowthaman U, Chodisetti SB, Agrewala JN, (2010) T cell help to B cells in germinal centers: putting the jigsaw together. Int Rev Immunol 29: 403–420.
63. Sun P, Fernandez S, Marovich MA, Palmer DR, Celluzzi CM, et al. (2009) Functional characterization of ex vivo blood myeloid and plasmacytoid dendritic cells after infection with dengue virus. Virology 383: 207–215.
64. Libraty DH, Pichyangkul S, Ajariyakhajorn C, Endy TP, Ennis FA, (2001) Human dendritic cells are activated by dengue virus infection: enhancement by gamma interferon and implications for disease pathogenesis. J Virol 75: 3501– 3508.
65. Liew FY, Millott S, Parkinson C, Palmer RM, Moncada S, (1990) Macrophage killing of Leishmania parasite in vivo is mediated by nitric oxide from L–arginine. J Immunol 144: 4794–4797.
66. Shiloh MU, Nathan CF, (2000) Reactive nitrogen intermediates and the pathogenesis of Salmonella and Mycobacteria. Curr Opin Microbiol 3: 35–42.
67. Lonardoni MVC, Russo M, Jancar S, (2000) Essential role of platelet activating factor in control of Leishmania amazonensis infection. Infect Immun 68: 6355–6361.